Invesco
AVBP icon

Invesco’s ArriVent BioPharma AVBP Stock Holding History

Invesco’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.15M Buy
32,966
+9,025
+38% +$266K ﹤0.01% 2857
2026
Q1 		$552K Buy
23,941
+7,049
+42% +$159K ﹤0.01% 3123
2025
Q4 		$340K Buy
16,892
+1,876
+12% +$39K ﹤0.01% 3336
2025
Q3 		$277K Sell
15,016
-33
-0.2% -$648 ﹤0.01% 3448
2025
Q2 		$328K Sell
15,049
-81
-0.5% -$1.68K ﹤0.01% 3330
2025
Q1 		$280K Sell
15,130
-209
-1% -$5.12K ﹤0.01% 3383
2024
Q4 		$409K Buy
+15,339
New +$440K ﹤0.01% 3318

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco's AVBP Position: Q2 2026 in Review

Invesco increased its ArriVent BioPharma (AVBP) stake by 38% in Q2 2026, buying an estimated $266K and bringing the position to 32,966 shares worth $1.15M. The position accounts for ﹤0.01% of the portfolio, ranked #2857.

Invesco first reported a position in AVBP in Q4 2024 and has held it in 7 quarters since. 158 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Invesco held 32,966 shares of ArriVent BioPharma worth $1.15M as of Q2 2026.
  • Invesco bought 9,025 ArriVent BioPharma shares in Q2 2026, an estimated $266K.
  • ArriVent BioPharma made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #2857 holding.
  • Invesco first reported a position in ArriVent BioPharma in Q4 2024 and has held it in 7 quarters since.
  • 158 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.